CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 86 enrolled
Drug / intervention
Varenicline +2 moredrug
Likely dose
Varenicline 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02202499
NCT02202499Early Ph 1Completed

Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence: Intervention Development and Feasibility Trial

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Jul 29, 2014·Updated Nov 27, 2020

In Brief

A Early Phase 1 clinical trial evaluating Varenicline, Counseling and Support Materials, and 1 other intervention for Smoking Cessation and Tobacco Dependence. Completed, enrolled 86 participants across 1 site.

Detailed Summary

The purpose of this Pilot feasibility study is to find out the effect of different behavioral treatments along with different duration of a drug called varenicline, on smoking behavior and quitting smoking. Varenicline, also known as Chantix™, is an FDA-approved medication that has been shown to help people quit smoking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Early Ph 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 29, 2014
Enrollment StartJul 17, 2014
Primary CompletionDec 11, 2015
Study CompletionJun 14, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.9 years ago

Interventions

Vareniclinedrug

All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.

Counseling and Support Materialsother

Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.

Laboratory Assessmentsother

The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.